Format

Send to

Choose Destination
JIMD Rep. 2018;41:53-62. doi: 10.1007/8904_2018_98. Epub 2018 Apr 14.

Alkaptonuria Severity Score Index Revisited: Analysing the AKUSSI and Its Subcomponent Features.

Author information

1
Costello Medical, Cambridge, UK. bryony.langford@costellomedical.com.
2
Costello Medical, Cambridge, UK.
3
AKU Society, Cambridge, UK.
4
Department of Musculoskeletal Biology, University of Liverpool, Liverpool, UK.
5
Royal Liverpool University Hospital, Liverpool, UK.

Abstract

BACKGROUND:

Alkaptonuria (AKU) is a rare disorder with no licensed treatment; nitisinone may reduce symptoms and progression. The All Alkaptonuria Severity Score Index (AKUSSI) measures disease severity in clinical, joint and spine domains, with 57 subcomponent feature scores. Our primary aim was to assess tools for validating scores such as the AKUSSI by detecting relationships between features both before and during nitisinone treatment.

METHODS:

AKUSSI measurements from nitisinone-treated patients visiting the National AKU Centre between 01-Jun-2012 and 31-May-2016 were analysed pre-treatment, at first treatment and annually to Year 3 post-treatment. Principal component analysis (PCA) and redundancy analysis assessed whether any AKUSSI features contributed little information to the overall score.

RESULTS:

65 AKU patients were included: 17 with a pre-treatment AKUSSI measurement (10 later received nitisinone) and 48 with a first measurement at their first treatment visit. In PCA, the first four principal components (PC1-PC4) explained ≥50% of AKUSSI variance at all visits (54.1-87.3%). Some features regularly dominated their domain's PC1: ears, aortic sclerosis, and nasal/temporal eye scores (clinical), pain-related scores (joint) and cervical, lumbar and thoracic spine scores (spine). Only the right-hand/wrist score was consistently redundant. Right eye (nasal) and left ear scores were redundant pre-treatment, potentially correlating with other dominant clinical PC1 features.

CONCLUSIONS:

PCA and redundancy analysis supported the AKUSSI as a robust AKU disease severity measure, although some AKUSSI features could be removed for simplicity. For small patient populations and rare diseases, PCA and redundancy analysis together can aid validation of disease severity metrics.

KEYWORDS:

Alkaptonuria; Assessment; Efficacy; Nitisinone; Ochronosis; Severity

Supplemental Content

Full text links

Icon for Springer Icon for PubMed Central
Loading ...
Support Center